Veozah

Drug Overview

In the field of Endocrinology, managing the complex hormonal shifts associated with menopause is essential for preserving a patient’s quality of life. Veozah is an innovative, non-hormonal medication classified within the NK3 Receptor Antagonist drug class. For decades, the primary treatment for menopausal vasomotor symptoms (hot flashes and night sweats) has been systemic estrogen therapy. However, Veozah represents a paradigm shift. It is a precise Targeted Therapy that works directly within the brain’s temperature-control center, offering an empathetic and highly effective solution for patients who cannot or choose not to use traditional estrogen-based treatments.

This medication provides a vital alternative for international patients dealing with chronic hormonal imbalances, especially those with a history of hormone-receptor-positive endocrine malignancies (such as certain breast cancers) where standard estrogen therapy is strictly contraindicated.

• Generic Name: Fezolinetant
• US Brand Names: Veozah
• Drug Category: [Endocrinology] / Menopausal Health
• Drug Class: NK3 Receptor Antagonist
• Route of Administration: Oral (Tablet)
• FDA Approval Status: FDA-approved (May 2023) for the treatment of moderate to severe vasomotor symptoms (hot flashes and night sweats) caused by menopause.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Veozah works, one must look at the brain’s hypothalamus, specifically a group of nerves known as KNDy (kisspeptin, neurokinin B, dynorphin) neurons. These neurons act as the body’s internal thermostat.

In a premenopausal woman, estrogen maintains a healthy balance by keeping these KNDy neurons regulated. During menopause, estrogen levels drop significantly. Without the negative feedback from estrogen, these KNDy neurons become overactive and enlarge. They begin to release excessive amounts of a brain chemical called neurokinin B (NKB). This excess NKB binds to specific receptors (NK3 receptors) in the brain’s thermoregulatory center, falsely signaling to the body that it is overheating. In response, the body triggers a massive heat-dissipation response: blood vessels rush to the skin surface (flushing) and the sweat glands activate (sweating), causing a severe hot flash.

Veozah is not a Biologic or a typical hormone, but it acts through the competitive antagonism of hormone receptors. It binds directly to the NK3 receptors, physically blocking neurokinin B from attaching. By blocking this signal, Veozah calms the overactive KNDy neurons and restores balance to the brain’s temperature control center. Unlike Hormone Replacement Therapy, which replaces systemic estrogen to quiet the nerves, Veozah precisely targets the source of the hot flash without exposing the rest of the body to estrogenic effects.

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved indication for Veozah is the treatment of moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes and night sweats, associated with menopause.

Other Approved & Off-Label Uses

Because Veozah is a highly specialized Targeted Therapy, its primary focus remains on menopausal symptoms. However, its unique non-hormonal mechanism allows for specific, related endocrine applications:

• Primary Endocrinology Indications:
  • Vasomotor Symptom Management: Restoring thermoregulatory balance in the hypothalamus to significantly reduce the frequency and severity of daily hot flashes.
  • Endocrine Malignancy Support (Off-Label Context): Used to treat severe hot flashes in breast cancer survivors or patients on estrogen-blocking therapies (like tamoxifen or aromatase inhibitors), where introducing estrogen would be dangerous.
  • Sleep Quality Improvement: By reducing severe night sweats, this medication indirectly restores the natural circadian rhythm of sleep disrupted by menopausal hormonal shifts.

Dosage and Administration Protocols

Veozah is administered as a daily oral tablet. Because it is not a hormone, it does not require complex cyclic dosing or titration schedules commonly associated with estrogen therapies.

Administration Timing: Veozah should be taken at approximately the same time every day to maintain stable blood levels of the medication. It can be taken with or without food. If a dose is missed, it should be taken as soon as possible that same day, and the regular schedule should resume the following day.

Patient Populations and Adjustments:

• Hepatic Insufficiency: Veozah is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C).
• Renal Insufficiency: It is not recommended for patients with severe renal impairment (eGFR less than 30 mL/min).
• Drug Interactions: Veozah should not be used with CYP1A2 inhibitors (such as certain antibiotics or antidepressants), as these can dangerously increase the levels of the drug in the blood.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

The clinical efficacy of Veozah is strongly supported by the SKYLIGHT 1 and SKYLIGHT 2 clinical trial programs (with data spanning 2020-2026). In these robust, placebo-controlled studies, Veozah demonstrated rapid and sustained relief for menopausal women.

Research data highlights its efficacy in achieving target symptom reduction. Women taking the 45 mg daily dose experienced a mean reduction of 2.5 to 3.2 hot flashes per day over the placebo group, representing a roughly 60 percent reduction in total hot flash frequency from their baseline. Furthermore, patients reported a significant decrease in the severity of the hot flashes that did occur.

While Veozah is not an Incretin Mimetic and does not lead to a percentage of weight loss or improvements in HbA1c percentage, its metabolic safety is well-documented. Importantly, studies confirm that because it is non-hormonal, it does not stimulate the uterine lining and does not negatively impact skeletal health, maintaining stable Bone Mineral Density (BMD) percentages in aging women.

Safety Profile and Side Effects

There is no Black Box Warning associated with Veozah. However, it carries a very specific warning regarding liver health.

Common Side Effects (>10%)

• Gastrointestinal: Abdominal pain and mild diarrhea.
• Neurological: Insomnia (difficulty sleeping).
• Musculoskeletal: Back pain.
• Paradoxical Effects: Mild, infrequent hot flushes as the body adjusts to the receptor blockade.

Serious Adverse Events

• Hepatic Transaminase Elevation: The most serious risk is drug-induced liver injury. Veozah can cause elevated liver enzymes (ALT and AST), which can lead to severe liver damage if left unmonitored.
• Hypersensitivity: Rare allergic reactions.

Management Strategies

Because of the risk of liver injury, strict hepatic monitoring is the primary safety strategy. This medication does not affect blood sugar, so routine glucose monitoring or emergency glucagon kits are not required. A “sick day” protocol simply involves holding the medication and contacting a doctor if symptoms of liver distress occur, such as yellowing of the eyes, dark urine, or severe right-sided stomach pain.

Research Areas

Direct Clinical Connections

Active research is currently focused on Veozah’s interaction with the hypothalamic-pituitary-adrenal (HPA) axis and the broader central nervous system. By blocking the NK3 receptor, researchers are studying how lowering the physical stress of severe hot flashes indirectly lowers daily cortisol spikes, thereby improving overall metabolic health and potentially improving insulin sensitivity in menopausal women.

Generalization

In the wider scope of Endocrinology, the successful development of Veozah is driving research into other Novel Delivery Systems and related non-hormonal targets for menopausal care. Active clinical trials (2024-2026) are evaluating the long-term impact of NK3 antagonists on sleep architecture and mood disorders associated with the menopause transition.

Severe Disease & Prevention

Current research is validating the drug’s efficacy in preventing the long-term cardiovascular consequences of severe sleep deprivation. By effectively eliminating night sweats, Veozah helps prevent the chronic fatigue and subsequent metabolic syndrome that often plagues women suffering from severe menopausal symptoms.

Disclaimer: Information regarding Veozah’s potential to improve insulin sensitivity by lowering cortisol spikes, its impact on long-term sleep architecture and mood disorders, and the prevention of metabolic syndrome via thermoregulatory stabilization should be considered exploratory unless supported by definitive clinical evidence. While these represent significant frontiers in non-hormonal menopausal care and the management of the HPA axis during the menopausal transition, they are not yet applicable to all clinical scenarios or standard of care protocols.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Organ Function: Baseline Hepatic monitoring is absolutely mandatory. Physicians must evaluate baseline ALT, AST, and total bilirubin levels before prescribing.
• Renal Function: A baseline kidney function test (eGFR) to ensure safe drug clearance.
• Diagnostics: While not always required if symptoms are classic, fasting hormone panels (FSH and Estradiol) may be drawn to confirm the patient is in menopause.
• Screening: Review of current medications to ensure no contraindicated CYP1A2 inhibitors are being used.

Monitoring and Precautions

• Vigilance: Strict follow-up testing is required. Liver blood tests must be performed at 3 months, 6 months, and 9 months after starting Veozah to monitor for asymptomatic liver enzyme elevations.
• Lifestyle: Medical Nutrition Therapy (MNT) remains helpful. Patients are encouraged to avoid known hot flash triggers such as spicy foods, caffeine, and alcohol. Weight-bearing exercise for bone health is strongly recommended, as Veozah does not provide the bone-protecting benefits of estrogen.
• “Do’s and Don’ts” list:
  • DO complete all your scheduled liver blood tests; they are vital for your safety.
  • DO take the medication at the same time every day to keep levels steady.
  • DON’T start any new medications or herbal supplements without telling your doctor, as they may interact with how your liver processes Veozah.
  • DON’T ignore signs of liver problems, such as unexplained nausea, fatigue, or jaundice.

Legal Disclaimer

This guide is intended for educational and informational purposes only and does not constitute formal medical advice, diagnosis, or treatment. Veozah is a specialized Targeted Therapy that must be prescribed and closely monitored by a qualified healthcare professional, such as a primary care provider, gynecologist, or endocrinologist. Always consult your physician regarding any changes to your treatment plan. Clinical data and protocols are accurate as of current standards through 2026.